231 related articles for article (PubMed ID: 32067794)
1. Reply to Alessia Cimadamore, Marina Scarpelli, Liang Cheng, et al's Letter to the Editor, re: Maria Chiara Sighinolfi, Bernardo Rocco's Words of Wisdom re: EAU Guidelines: Prostate Cancer 2019. Mottet N, van den Bergh RCN, Briers E, et al. https://uroweb.org/guideline/prostate-Cancer/. Eur Urol 2019, 76:871.
Sighinolfi MC; Rocco B
Eur Urol; 2020 May; 77(5):e128-e129. PubMed ID: 32067794
[No Abstract] [Full Text] [Related]
2. Re: Maria Chiara Sighinolfi, Bernardo Rocco's Words of Wisdom re: EAU Guidelines: Prostate Cancer 2019. Mottet N, van den Bergh RCN, Briers E, et al. https://uroweb.org/guideline/prostate-Cancer/. Eur Urol 2019;76:871.
Cimadamore A; Scarpelli M; Cheng L; Lopez-Beltran A; Galosi AB; Montorsi F; Montironi R
Eur Urol; 2020 May; 77(5):e122-e127. PubMed ID: 32089357
[No Abstract] [Full Text] [Related]
3. Reply to Alessia Cimadamore, Liang Cheng, Marina Scarpelli, et al's Letter to the Editor re: Alfonso Gómez de Liaño Lista, Nick van Dijk, Guillermo de Velasco Oria de Rueda, et al. Clinical Outcome After Progressing to Frontline and Second-line Anti-PD-1/PD-L1 in Advanced Urothelial Cancer. Eur Urol 2020;77:269-76. Progression and Hyperprogression Versus Pseudoprogression: Morphologic Documentation.
van Dijk N; Gómez de Liaño Lista A; Szabados B; Powles T; van der Heijden MS
Eur Urol; 2021 Jan; 79(1):e20-e21. PubMed ID: 33153815
[No Abstract] [Full Text] [Related]
4. Reply to Alessia Cimadamore, Liang Cheng, Antonio Lopez-Beltran, Marina Scarpelli, and Rodolfo Montironi's Letter to the Editor re: Scott Wilkinson, Huihui Ye, Fatima Karzai, et al. Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.03.009: Focus on Intraductal Carcinoma of the Prostate.
Wilkinson S; Ye H; Lis RT; Sowalsky AG
Eur Urol; 2021 Sep; 80(3):e83-e84. PubMed ID: 34148711
[No Abstract] [Full Text] [Related]
5. Reply to Michael Froehner, Rainer Koch, and Markus Graefen's Letter to the Editor re: Nicolas Mottet, Roderick C.N. van den Bergh, Erik Briers, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol 2021;79:243-62. Comorbidity Measurement in Patients with Prostate Cancer.
van den Bergh RCN; O'Hanlon S; Cornford P; Mottet N;
Eur Urol; 2021 May; 79(5):e139-e140. PubMed ID: 33608157
[No Abstract] [Full Text] [Related]
6. Re: Nicolas Mottet, Roderick C.N. van den Bergh, Erik Briers, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol 2021;79:243-62: Comorbidity Measurement in Patients with Prostate Cancer.
Froehner M; Koch R; Graefen M
Eur Urol; 2021 May; 79(5):e138. PubMed ID: 33612374
[No Abstract] [Full Text] [Related]
7. Reply to Rodolfo Montironi, Liang Cheng, Marina Scarpelli, Alessia Cimadamore, Francesco Montorsi, and Antonio Lopez-Beltran's Letter to the Editor re: Gillian Vandekerkhove, Werner J. Struss, Matti Annala, et al. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer. Eur Urol 2019;75:667-75: How Does Circulating DNA Reach the Blood Stream?
Wyatt AW; Chi KN; Gleave ME
Eur Urol; 2019 Sep; 76(3):e73-e74. PubMed ID: 31167749
[No Abstract] [Full Text] [Related]
8. Re: Philip Cornford, Roderick C.N. van den Bergh, Erik Briers, et al. EAU-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. Eur Urol 2021;79:263-82.
von Eyben FE
Eur Urol; 2021 Jun; 79(6):e176. PubMed ID: 33712301
[No Abstract] [Full Text] [Related]
9. Reply to Alessia Cimadamore, Antonio Lopez-Beltran, Marina Scarpelli, and Rodolfo Montironi's Letter to the Editor re: Timothy D. Jones, Liang Cheng. Histologic Grading of Bladder Tumors: Using Both the 1973 and 2004/2016 World Health Organization Systems in Combination Provides Valuable Information for Establishing Prognostic Risk Groups. Eur Urol 2021;79:489-91: Towards Molecular Grading of Urothelial Tumors.
Jones TD; Cheng L
Eur Urol; 2021 Jun; 79(6):e174-e175. PubMed ID: 33824030
[No Abstract] [Full Text] [Related]
10. Reply to Rodolfo Montironi, Marina Scarpelli, Alessia Cimadamore, and Gregor Mikuz's Letter to the Editor re: Theo van der Kwast, Fredrik Liedberg, Peter C. Black, et al. International Society of Urological Pathology Expert Opinion on Grading of Urothelial Carcinoma. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2021.03.017. Focus on Our Personal Recollections and Observations.
van der Kwast T; Van Rhijn B; Kamat A; Cheng L
Eur Urol Focus; 2022 May; 8(3):885-886. PubMed ID: 33992577
[No Abstract] [Full Text] [Related]
11. Re: Henk G. van der Poel, Roderick C.N. van den Bergh, Erik Briers, et al. Focal Therapy in Primary Localised Prostate Cancer: The European Association of Urology Position in 2018. Eur Urol 2018;74:84-91.
Valerio M; Emberton M; Ahmed HU
Eur Urol; 2019 Feb; 75(2):e21-e22. PubMed ID: 30224194
[No Abstract] [Full Text] [Related]
12. Reply to Xueliang Zhou and Xinwei Han's Letter to the Editor re: Thomas Van den Broeck, Roderick C.N. van den Bergh, Nicolas Arfi, et al. Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review. Eur Urol 2019;75:967-87.
Van den Broeck T; Mottet N; Lam T
Eur Urol; 2019 Jul; 76(1):e16. PubMed ID: 30967298
[No Abstract] [Full Text] [Related]
13. Reply to Massimo Valerio, Mark Emberton, and Hashim U. Ahmed's Letter to the Editor re: Henk G. van der Poel, Roderick C.N. van den Bergh, Erik Briers, et al. Focal Therapy in Primary Localised Prostate Cancer: The European Association of Urology Position in 2018. Eur Urol 2018;74:84-91.
van der Poel HG; van den Bergh RCN; Briers E; Cornford P; Govorov A; Henry AM; Lam TB; Mason MD; Rouvière O; De Santis M; Wiegel T; Willemse PM; van Poppel H; Mottet N
Eur Urol; 2019 Feb; 75(2):e23-e24. PubMed ID: 30237024
[No Abstract] [Full Text] [Related]
14. Reply to Henk G. van der Poel, Tessa Buckle and Renato Valdes Olmos' letter to the editor re: Steven Joniau, Laura Van den Bergh, Evelyne Lerut, et al. Mapping of pelvic lymph node metastases in prostate cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2012.06.057.
Joniau S; Van den Bergh L
Eur Urol; 2013 Feb; 63(2):e21-2. PubMed ID: 23149147
[No Abstract] [Full Text] [Related]
15. Reply to Kwang Hyun Kim and Koon Ho Rha's letter to the editor Re: Steven Joniau, Laura Van den Bergh, Evelyne Lerut, et al. Mapping of pelvic lymph node metastases in prostate cancer. Eur Urol 2013;63:450-8.
Tosco L; Van den Bergh L; Joniau S
Eur Urol; 2013 Sep; 64(3):e57-8. PubMed ID: 23769590
[No Abstract] [Full Text] [Related]
16. Reply to Luca Sarchi, Maria Chiara Sighinolfi, Simone Assumma, et al.'s Letter to Editor re: Carlo A. Bravi, Marco Paciotti, Eleonora Balestrazzi, et al. Outcomes of Robot-assisted Radical Prostatectomy with the Hugo RAS Surgical System: Initial Experience at a High-volume Robotic Center. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2023.01.008.
Bravi CA; Mottrie A
Eur Urol Focus; 2023 Sep; 9(5):843. PubMed ID: 36898944
[No Abstract] [Full Text] [Related]
17. Re: Nicolas Mottet, Joaquim Bellmunt, Erik Briers, et al. EAU-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. European Association of Urology; 2017. http://uroweb.org/guideline/prostate-cancer: How to Assess the Efficacy of Medical Castration.
Morote J; Comas I; Planas J
Eur Urol; 2018 May; 73(5):e134-e135. PubMed ID: 29452710
[No Abstract] [Full Text] [Related]
18. Reply to Bernardo Rocco and Maria Chiara Sighinolfi's Letter to the Editor re: Romain Diamand, Jean-Baptiste Roche, Elena Lievore, et al. External Validation of Models for Prediction of Side-specific Extracapsular Extension in Prostate Cancer Patients Undergoing Radical Prostatectomy. Eur Urol Focus 2023;9:309-16.
Diamand R; Albisinni S
Eur Urol Focus; 2023 May; 9(3):548. PubMed ID: 36372734
[No Abstract] [Full Text] [Related]
19. Re: Thomas Van den Broeck, Roderick C.N. van den Bergh, Nicolas Arfi, et al. Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review. Eur Urol 2019;75:967-87.
Zhou X; Han X
Eur Urol; 2019 Jul; 76(1):e15. PubMed ID: 30948226
[No Abstract] [Full Text] [Related]
20. Reply to Roderick C.N. van den Bergh, Olivier Rouvière, and Theodorus van der Kwast's Letter to the Editor re: Andrew Vickers, Sigrid V. Carlsson, Matthew Cooperberg. Routine Use of Magnetic Resonance Imaging for Early Detection of Prostate Cancer Is Not Justified by the Clinical Trial Evidence. Eur Urol 2020;78:304-6. Prebiopsy MRI: Through the Looking Glass.
Vickers A; Carlsson SV; Cooperberg M
Eur Urol; 2020 Sep; 78(3):314-315. PubMed ID: 32631742
[No Abstract] [Full Text] [Related]
[Next] [New Search]
